{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:50:19Z","timestamp":1787165419277,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone to include a more intricate metabolic process that is, in part, still unknown. Similarly, this significantly increases the number of people with heart diseases who may be eligible for EMPA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study aimed to clarify the metabolic effect of EMPA on the human myocardial cell model by using orthogonal metabolomics, lipidomics, and proteomics approaches. The untargeted and multivariate analysis mimicked the fasting blood sugar level of T2DM patients (hyperglycemia: HG) and in the average blood sugar range (normal glucose: NG), with and without the addition of EMPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results highlighted that EMPA was able to modulate and partially restore the levels of multiple metabolites associated with cellular stress, which were dysregulated in the HG conditions, such as nicotinamide mononucleotide, glucose-6-phosphate, lactic acid, FA 22:6 as well as nucleotide sugars and purine\/pyrimidines. Additionally, EMPA regulated the levels of several lipid sub-classes, in particular dihydroceramide and triacylglycerols, which tend to accumulate in HG conditions resulting in lipotoxicity. Finally, EMPA counteracted the dysregulation of endoplasmic reticulum-derived proteins involved in cellular stress management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results could suggest an effect of EMPA on different metabolic routes, tending to rescue cardiomyocyte metabolic status towards a healthy phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04537-1","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:01:43Z","timestamp":1695477703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes"],"prefix":"10.1186","volume":"21","author":[{"given":"Lucia","family":"Scisciola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Chianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Caponigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Giovanna","family":"Basilicata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Salviati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Campiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-5792","authenticated-orcid":false,"given":"Michelangela","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Sommella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"issue":"1","key":"4537_CR1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13098-023-00998-y","volume":"15","author":"J Deng","year":"2023","unstructured":"Deng J, Yan F, Tian J, Qiao A, Yan D. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy. Diabetol Metab Syndr. 2023;15(1):35.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"4537_CR2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/cdt-20-302","volume":"11","author":"RHG Schwinger","year":"2021","unstructured":"Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11(1):263\u201376.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"8","key":"4537_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","volume":"9","author":"M Packer","year":"2021","unstructured":"Packer M. Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail. 2021;9(8):535\u201349.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"4537_CR4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"4","key":"4537_CR5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/biom12040542","volume":"12","author":"M Khalid","year":"2022","unstructured":"Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules. 2022;12(4):542.","journal-title":"Biomolecules."},{"issue":"1","key":"4537_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.12997\/jla.2019.8.1.26","volume":"8","author":"J Gollmer","year":"2019","unstructured":"Gollmer J, Zirlik A, Bugger H. Established and emerging mechanisms of diabetic cardiomyopathy. J Lipid Atheroscler. 2019;8(1):26\u201347.","journal-title":"J Lipid Atheroscler"},{"issue":"9","key":"4537_CR7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585\u2013607.","journal-title":"Nat Rev Cardiol"},{"key":"4537_CR8","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.705424","volume":"12","author":"A Tayanloo-Beik","year":"2021","unstructured":"Tayanloo-Beik A, Roudsari PP, Rezaei-Tavirani M, Biglar M, Tabatabaei-Malazy O, Arjmand B, et al. Diabetes and heart failure: multi-omics approaches. Front Physiol. 2021;12: 705424.","journal-title":"Front Physiol"},{"issue":"1","key":"4537_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12967-023-03928-8","volume":"21","author":"C Peng","year":"2023","unstructured":"Peng C, Zhang Y, Lang X, Zhang Y. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. J Transl Med. 2023;21(1):66.","journal-title":"J Transl Med"},{"key":"4537_CR10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12967-015-0661-3","volume":"13","author":"M Deidda","year":"2015","unstructured":"Deidda M, Piras C, Dessalvi CC, Locci E, Barberini L, Torri F, et al. Metabolomic approach to profile functional and metabolic changes in heart failure. J Transl Med. 2015;13:297.","journal-title":"J Transl Med"},{"issue":"5","key":"4537_CR11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/cells9051283","volume":"9","author":"A Faulkner","year":"2020","unstructured":"Faulkner A, Dang Z, Avolio E, Thomas AC, Batstone T, Lloyd GR, et al. Multi-omics analysis of diabetic heart disease in the db\/db model reveals potential targets for treatment by a longevity-associated gene. Cells. 2020;9(5):1283.","journal-title":"Cells."},{"key":"4537_CR12","volume":"9","author":"Y Xi","year":"2022","unstructured":"Xi Y, Chen D, Dong Z, Zhang J, Lam H, He J, et al. Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. Front Cardiovasc Med. 2022;9: 999254.","journal-title":"Front Cardiovasc Med"},{"key":"4537_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13098-017-0249-6","volume":"9","author":"S Dong","year":"2017","unstructured":"Dong S, Zhang R, Liang Y, Shi J, Li J, Shang F, et al. Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC\/Q-TOF\/MS analysis. Diabetol Metab Syndr. 2017;9:56.","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"4537_CR14","volume":"13","author":"N Srinivas","year":"2021","unstructured":"Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: delving into the potential benefits of cardiorenal protection beyond the treatment of type-2 diabetes mellitus. Cureus. 2021;13(8): e16868.","journal-title":"Cureus"},{"key":"4537_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17\u201331.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"4537_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","volume":"117","author":"M Packer","year":"2021","unstructured":"Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117(1):74\u201384.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"4537_CR17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054100","volume":"12","author":"R Thirumathyam","year":"2022","unstructured":"Thirumathyam R, Richter EA, Goetze JP, Fenger M, Van Hall G, Dixen U, et al. Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial. BMJ Open. 2022;12(8): e054100.","journal-title":"BMJ Open"},{"key":"4537_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00824-4","author":"M Packer","year":"2023","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol. 2023. https:\/\/doi.org\/10.1038\/s41569-022-00824-4.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"4537_CR19","doi-asserted-by":"crossref","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. 2021;10(6):e018298.","journal-title":"J Am Heart Assoc."},{"key":"4537_CR20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","volume":"5","author":"B Xie","year":"2022","unstructured":"Xie B, Ramirez W, Mills AM, Huckestein BR, Anderson M, Pangburn MM, et al. Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6\/J mice. Curr Res Physiol. 2022;5:232\u20139.","journal-title":"Curr Res Physiol"},{"issue":"2","key":"4537_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/ehz621","volume":"41","author":"D Fitchett","year":"2020","unstructured":"Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, et al. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2020;41(2):209\u201317.","journal-title":"Eur Heart J"},{"issue":"2","key":"4537_CR22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/eurheartj\/ehz730","volume":"41","author":"C Solis-Herrera","year":"2020","unstructured":"Solis-Herrera C, Sheikh O, Chilton R. A new perspective on lowering CV risk from hypoglycaemia. Eur Heart J. 2020;41(2):218\u201320.","journal-title":"Eur Heart J"},{"issue":"1","key":"4537_CR23","doi-asserted-by":"crossref","first-page":"9544","DOI":"10.1038\/s41598-021-89149-9","volume":"11","author":"JM Seefeldt","year":"2021","unstructured":"Seefeldt JM, Lassen TR, Hjortbak MV, Jespersen NR, Kvist F, Hansen J, et al. Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci Rep. 2021;11(1):9544.","journal-title":"Sci Rep"},{"issue":"1","key":"4537_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","volume":"21","author":"S Chen","year":"2022","unstructured":"Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):45.","journal-title":"Cardiovasc Diabetol"},{"key":"4537_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01754-2","author":"L Scisciola","year":"2023","unstructured":"Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina Cataldo V, et al. Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors. Cardiovasc Diabetol. 2023. https:\/\/doi.org\/10.1186\/s12933-023-01754-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"4537_CR26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/1440-1681.13470","volume":"48","author":"G Tian","year":"2021","unstructured":"Tian G, Yu Y, Deng H, Yang L, Shi X, Yu B. Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1\/PTEN\/Akt pathway. Clin Exp Pharmacol Physiol. 2021;48(6):837\u201345.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4537_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114233","volume":"234","author":"D Carbone","year":"2022","unstructured":"Carbone D, Vestuto V, Ferraro MR, Ciaglia T, Pecoraro C, Sommella E, et al. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: from phenotype screening to target identification. Eur J Med Chem. 2022;234: 114233.","journal-title":"Eur J Med Chem"},{"key":"4537_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.463124","volume":"1673","author":"F Merciai","year":"2022","unstructured":"Merciai F, Musella S, Sommella E, Bertamino A, D\u2019Ursi AM, Campiglia P. Development and application of a fast ultra-high performance liquid chromatography-trapped ion mobility mass spectrometry method for untargeted lipidomics. J Chromatogr A. 2022;1673: 463124.","journal-title":"J Chromatogr A"},{"issue":"24","key":"4537_CR29","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.3390\/cancers14246262","volume":"14","author":"E Sommella","year":"2022","unstructured":"Sommella E, Capaci V, Aloisio M, Salviati E, Campiglia P, Molinario G, et al. A Label-free proteomic approach for the identification of biomarkers in the exosome of endometrial cancer serum. Cancers. 2022;14(24):6262.","journal-title":"Cancers."},{"issue":"1","key":"4537_CR30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121\u201341.","journal-title":"Circ Res"},{"issue":"1","key":"4537_CR31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12967-021-02935-x","volume":"19","author":"Y Lin","year":"2021","unstructured":"Lin Y, Fu S, Yao Y, Li Y, Zhao Y, Luo L. Heart failure with preserved ejection fraction based on aging and comorbidities. J Transl Med. 2021;19(1):291.","journal-title":"J Transl Med"},{"issue":"2","key":"4537_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15420\/cfr.2018.18.2","volume":"4","author":"GM Rosano","year":"2018","unstructured":"Rosano GM, Vitale C. Metabolic modulation of cardiac metabolism in heart failure. Card Fail Rev. 2018;4(2):99\u2013103.","journal-title":"Card Fail Rev"},{"issue":"1","key":"4537_CR33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12967-023-04361-7","volume":"21","author":"Q Yan","year":"2023","unstructured":"Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023;21(1):519.","journal-title":"J Transl Med"},{"issue":"3","key":"4537_CR34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","volume":"27","author":"J Yoshino","year":"2018","unstructured":"Yoshino J, Baur JA, Imai SI. NAD(+) intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513\u201328.","journal-title":"Cell Metab"},{"issue":"7","key":"4537_CR35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCRESAHA.118.312498","volume":"123","author":"AE Kane","year":"2018","unstructured":"Kane AE, Sinclair DA. Sirtuins and NAD(+) in the development and treatment of metabolic and cardiovascular diseases. Circ Res. 2018;123(7):868\u201385.","journal-title":"Circ Res"},{"issue":"21","key":"4537_CR36","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","volume":"137","author":"N Diguet","year":"2018","unstructured":"Diguet N, Trammell SAJ, Tannous C, Deloux R, Piquereau J, Mougenot N, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation. 2018;137(21):2256\u201373.","journal-title":"Circulation"},{"issue":"1","key":"4537_CR37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12912-021-00558-7","volume":"20","author":"LH Chiao","year":"2021","unstructured":"Chiao LH, Wu CF, Tzeng IS, Teng AN, Liao RW, Yu LY, et al. Exploring factors influencing the retention of nurses in a religious hospital in Taiwan: a cross-sectional quantitative study. BMC Nurs. 2021;20(1):42.","journal-title":"BMC Nurs"},{"issue":"4","key":"4537_CR38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","volume":"14","author":"J Yoshino","year":"2011","unstructured":"Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet\u2014and age-induced diabetes in mice. Cell Metab. 2011;14(4):528\u201336.","journal-title":"Cell Metab"},{"issue":"6","key":"4537_CR39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/jcm11061470","volume":"11","author":"DM Keller","year":"2022","unstructured":"Keller DM, Ahmed N, Tariq H, Walgamage M, Walgamage T, Mohammed A, et al. SGLT2 inhibitors in type 2 diabetes mellitus and heart failure-a concise review. J Clin Med. 2022;11(6):1470.","journal-title":"J Clin Med."},{"issue":"1","key":"4537_CR40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour AA, Korkmaz-Icoz S, Loganathan S, Ruppert M, Sayour VN, Olah A, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med. 2019;17(1):127.","journal-title":"J Transl Med"},{"key":"4537_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100933","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Graffunder FP, Ternes CMP, Fernandes A, Rocha AV, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36: 100933.","journal-title":"EClinicalMedicine"},{"key":"4537_CR42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","volume":"6","author":"Y Maejima","year":"2019","unstructured":"Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med. 2019;6:186.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"4537_CR43","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8(1):6791.","journal-title":"Sci Rep"},{"key":"4537_CR44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901340","volume":"13","author":"Z Wicik","year":"2022","unstructured":"Wicik Z, Nowak A, Jarosz-Popek J, Wolska M, Eyileten C, Siller-Matula JM, et al. Characterization of the SGLT2 interaction network and its regulation by SGLT2 Inhibitors: a bioinformatic analysis. Front Pharmacol. 2022;13: 901340.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4537_CR45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.109.888479","volume":"3","author":"T Kato","year":"2010","unstructured":"Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail. 2010;3(3):420\u201330.","journal-title":"Circ Heart Fail"},{"key":"4537_CR46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","volume":"107","author":"B Giri","year":"2018","unstructured":"Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother. 2018;107:306\u201328.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4537_CR47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cardiores.2006.08.020","volume":"72","author":"LC Heather","year":"2006","unstructured":"Heather LC, Cole MA, Lygate CA, Evans RD, Stuckey DJ, Murray AJ, et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res. 2006;72(3):430\u20137.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"4537_CR48","volume":"9","author":"JP Zhao","year":"2014","unstructured":"Zhao JP, Levy E, Fraser WD, Julien P, Delvin E, Montoudis A, et al. Circulating docosahexaenoic acid levels are associated with fetal insulin sensitivity. PLoS ONE. 2014;9(1): e85054.","journal-title":"PLoS ONE"},{"issue":"11","key":"4537_CR49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","volume":"146","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, et al. Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF. Circulation. 2022;146(11):808\u201318.","journal-title":"Circulation"},{"issue":"1","key":"4537_CR50","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41598-019-39441-6","volume":"9","author":"C Papandreou","year":"2019","unstructured":"Papandreou C, Li J, Liang L, Bullo M, Zheng Y, Ruiz-Canela M, et al. Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism. Sci Rep. 2019;9(1):2892.","journal-title":"Sci Rep"},{"issue":"14","key":"4537_CR51","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.3390\/ijms23147966","volume":"23","author":"E Zugner","year":"2022","unstructured":"Zugner E, Yang HC, Kotzbeck P, Boulgaropoulos B, Sourij H, Hagvall S, et al. Differential in vitro effects of SGLT2 inhibitors on mitochondrial oxidative phosphorylation, glucose uptake and cell metabolism. Int J Mol Sci. 2022;23(14):7966.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4537_CR52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/dom.14018","volume":"22","author":"S Mulder","year":"2020","unstructured":"Mulder S, Hammarstedt A, Nagaraj SB, Nair V, Ju W, Hedberg J, et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes Metab. 2020;22(7):1157\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"4537_CR53","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154936","volume":"127","author":"R Marfella","year":"2022","unstructured":"Marfella R, D\u2019Onofrio N, Trotta MC, Sardu C, Scisciola L, Amarelli C, et al. Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127: 154936.","journal-title":"Metabolism"},{"issue":"2","key":"4537_CR54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.","journal-title":"Metabolites"},{"issue":"1","key":"4537_CR55","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41467-022-28496-1","volume":"13","author":"C Wittenbecher","year":"2022","unstructured":"Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, Jager S, Kuxhaus O, et al. Dihydroceramide\u2014and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat Commun. 2022;13(1):936.","journal-title":"Nat Commun"},{"key":"4537_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847407","author":"G Ahuja","year":"2019","unstructured":"Ahuja G, Bartsch D, Yao W, Geissen S, Frank S, Aguirre A, et al. Loss of genomic integrity induced by lysosphingolipid imbalance drives ageing in the heart. EMBO Rep. 2019. https:\/\/doi.org\/10.15252\/embr.201847407.","journal-title":"EMBO Rep"},{"issue":"10","key":"4537_CR57","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","volume":"116","author":"JM McGavock","year":"2007","unstructured":"McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170\u20135.","journal-title":"Circulation"},{"key":"4537_CR58","unstructured":"From the American Association of Neurological Surgeons ASoNC, O, Sacks D, Baxter B, et al 2018. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 13 6 612 32"},{"issue":"12","key":"4537_CR59","volume":"8","author":"DH Tran","year":"2019","unstructured":"Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc. 2019;8(12): e012673.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"4537_CR60","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, et al. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4537_CR61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174249","volume":"907","author":"P Kapadia","year":"2021","unstructured":"Kapadia P, Bikkina P, Landicho MA, Parekh S, Haas MJ, Mooradian AD. Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells. Eur J Pharmacol. 2021;907: 174249.","journal-title":"Eur J Pharmacol"},{"key":"4537_CR62","volume":"2012","author":"J Xu","year":"2012","unstructured":"Xu J, Zhou Q, Xu W, Cai L. Endoplasmic reticulum stress and diabetic cardiomyopathy. Exp Diabetes Res. 2012;2012: 827971.","journal-title":"Exp Diabetes Res"},{"issue":"1","key":"4537_CR63","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-023-04170-y","volume":"21","author":"G Pietrafesa","year":"2023","unstructured":"Pietrafesa G, De Zio R, Scorza SI, Armentano MF, Pepe M, Forleo C, et al. Targeting unfolded protein response reverts ER stress and ER Ca(2+) homeostasis in cardiomyocytes expressing the pathogenic variant of Lamin A\/C R321X. J Transl Med. 2023;21(1):340.","journal-title":"J Transl Med"},{"issue":"12","key":"4537_CR64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2018.12.003","volume":"45","author":"MC Florio","year":"2020","unstructured":"Florio MC, Magenta A, Beji S, Lakatta EG, Capogrossi MC. Aging, MicroRNAs, and heart failure. Curr Probl Cardiol. 2020;45(12): 100406.","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"4537_CR65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108830","volume":"34","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wang X, Yuan Z, Radford SJ, Liu C, Libutti SK, et al. Amino acids-Rab1A-mTORC1 signaling controls whole-body glucose homeostasis. Cell Rep. 2021;34(11): 108830.","journal-title":"Cell Rep"},{"issue":"3","key":"4537_CR66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10456-021-09768-8","volume":"24","author":"CE Benson","year":"2021","unstructured":"Benson CE, Southgate L. The DOCK protein family in vascular development and disease. Angiogenesis. 2021;24(3):417\u201333.","journal-title":"Angiogenesis"},{"issue":"18","key":"4537_CR67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"key":"4537_CR68","volume":"8","author":"YW Yu","year":"2021","unstructured":"Yu YW, Que JQ, Liu S, Huang KY, Qian L, Weng YB, et al. sodium-glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front Cardiovasc Med. 2021;8: 768214.","journal-title":"Front Cardiovasc Med"},{"key":"4537_CR69","volume":"9","author":"C Wen","year":"2021","unstructured":"Wen C, Zhou Y, Xu Y, Tan H, Pang C, Liu H, et al. The regulatory role of GBF1 on osteoclast activation through EIF2a mediated ER stress and novel marker FAM129A induction. Front Cell Dev Biol. 2021;9: 706768.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4537_CR70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yjmcc.2005.03.003","volume":"39","author":"MM Davidson","year":"2005","unstructured":"Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39(1):133\u201347.","journal-title":"J Mol Cell Cardiol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04537-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:11:14Z","timestamp":1700568674000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04537-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4537"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04537-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"662"}}